NCT00002913: Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer |
|
|
| Completed | 1 | 30 | US | paclitaxel, Anzatax, Asotax, TAX, Taxol, cisplatin, CACP, CDDP, CPDD, DDP, topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, filgrastim, G-CSF, Neupogen | National Cancer Institute (NCI) | Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer | 07/07 | | | |
NCT00842452: Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery |
|
|
| Completed | 1 | 26 | US | topotecan hydrochloride, pharmacological study | Steven Waggoner, MD, National Cancer Institute (NCI) | Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Vaginal Cancer, Vulvar Cancer | 04/11 | 04/11 | | |
